Abstract Number: 1580 • ACR Convergence 2021
Whole Blood Gene Expression and eQTL Analysis Implicate GGT7 and FADS2 in Gout Pathogenesis
Background/Purpose: Gene expression studies of whole blood represent a powerful approach for understanding the pathogenesis of gout because differentially expressed transcripts may reflect the activation…Abstract Number: 1581 • ACR Convergence 2021
Genetic Effects on the Transition from Hyperuricemia to Gout
Background/Purpose: There is clear evidence of genetic control of hyperuricemia resulting in increased gout risk, however genetic control of the transition from hyperuricemia to gout…Abstract Number: 1895 • ACR Convergence 2021
Achievement of Target Serum Uric Acid Among Gout Patients Treated with Long-term Urate Lowering Therapy in the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry
Background/Purpose: The American College of Rheumatology’s (ACR) 2012 guidelines for the management of gout recommend using a treat-to-target (T2T) approach to lower serum uric acid…Abstract Number: 1897 • ACR Convergence 2021
A Randomized Double-Blind Controlled Trial of Intensive Serum Urate Lowering with Oral Urate-Lowering Therapy for Erosive Gout
Background/Purpose: Bone erosion is a common consequence of tophaceous gout, and leads to joint deformity and disability. In small case series, intensive urate-lowering with intravenous…Abstract Number: 1899 • ACR Convergence 2021
Mortality in Patients with Sub-Optimally Treated Gout in the Veteran’s Health Administration: A National Retrospective Cohort Study
Background/Purpose: Patients with gout have an increased risk of mortality. Current ACR guidelines for the treatment of gout recommend a treat-to-target approach with titration of…Abstract Number: 1900 • ACR Convergence 2021
Urate Lowering Therapy in the Treatment of Gout: A Multicenter, Randomized, Double-blind Comparison of Allopurinol and Febuxostat Using a Treat-to-Target Strategy
Background/Purpose: Urate lowering therapy (ULT) is a cornerstone treatment in the management of gout. A paucity of data exists about the relative efficacy and safety…Abstract Number: L08 • ACR Convergence 2020
Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators)
Background/Purpose: Febuxostat and allopurinol are uric acid lowering agents. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency (EMA) recommended a post-authorization…Abstract Number: 0063 • ACR Convergence 2020
Novel Repurposed Drugs Against Joint Inflammation Reveal Potential Use for Gout Treatment: An In Silico, In Vitro and Clinical Study
Background/Purpose: Joint inflammation is a common feature across multiple rheumatic diseases. To deal with the induction of innate immune factors, targeting therapeutic targets such as…Abstract Number: 0152 • ACR Convergence 2020
Veterans with RA and Gout Identify Their Goals and How They Can Work with Clinicians to Achieve Their Goals
Background/Purpose: Understanding patient goals and concerns is essential for aligning treatment decisions with patient preferences and supporting effective patient-clinician partnerships. Yet, little is known about…Abstract Number: 0445 • ACR Convergence 2020
Dual-Energy CT in Gout Patients: Do All Color-Coded Lesions Actually Represent Monosodium Urate Crystals?
Background/Purpose: Dual-Energy CT (DECT) can acknowledge differences in tissue compositions and can color-code tissues with specific features including monosodium urate (MSU) crystals. However, when evaluating…Abstract Number: 0535 • ACR Convergence 2020
Provider Opinion and Support for Shared Decision-making in Gout Treatment: A Quality Improvement National Survey of Veterans Affairs Rheumatologists
Background/Purpose: To assess rheumatologists’ views and practices related to shared decision making (SDM) in gout treatment.Methods: We performed a cross-sectional electronic survey of rheumatologists at…Abstract Number: 0600 • ACR Convergence 2020
Gout Increases Length of Stay in Patients Hospitalized for Heart Failure Exacerbation
Background/Purpose: There is growing evidence that both the prevalence of gout and its burden on healthcare costs has increased over recent decades. It has been…Abstract Number: 0646 • ACR Convergence 2020
“An Apple Pie a Day Does Not Keep the Doctor Away”. Fictional Depictions of Gout in Contemporary Film and Television
Background/Purpose: Views about gout as a self-inflicted condition of dietary excess can contribute to stigma and lead to ineffective management strategies. Fictional portrayals of illness…Abstract Number: 0647 • ACR Convergence 2020
Dual-energy CT versus Ultrasound, Alone or in Combination, for the Diagnosis of Gout: A Diagnostic Performance Study
Background/Purpose: To examine the diagnostic accuracy of dual-energy computed tomography (DECT) vs. ultrasound or their combination for the diagnosis of gout.Methods: Using data from an…Abstract Number: 0648 • ACR Convergence 2020
Dual Energy CT Has Additional Prognostic Value over Clinical Measures in Gout Including Tophi: Best Evidence Synthesis
Background/Purpose: Dual Energy CT Scan (DECT) can detect monosodium urate crystals in joints and periarticular tissues. EULAR gout guidelines (Richette, 2020) recognized DECT's value in…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 83
- Next Page »
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 83
- Next Page »
Didn't find what you were looking for? Try the Advanced Search »